Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + capecitabine + oxaliplatin vs gemcitabine + cisplatin in first-line treatment of cholangiocarcinoma
2013-004854-46Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Apr 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in cholangiocarcinoma (CCA) comparing Gemcitabine + capecitabine + oxaliplatin with Gemcitabine + cisplatin (2 arms). Primary endpoint: progression-free survival. Started Apr 2014; status: completed.
02
Drugs
gemcitabinecapecitabineoxaliplatincisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2013-004854-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004854-46.